Immunogen, Inc.

Biotest Ag

Thomas Haeder

Benjamin Daelken

Christoph Uherek

Frank Osterroth

Christoph Bruecher

Gregor Schulz

Andrea Wartenberg-Demand

Silke Aigner

Chantal Zuber

André Engling

Steffen Zeng

Gabriele Niemann

Matthias Germer

Elmar Kraus

Niklas Czeloth

Marcus Gutscher

Katrin Bernoester

Martin Koenig

Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.

Uses of immunoconjugates targeting CD138

Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.

Immunoconjugates targeting CD138 and uses thereof

Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.

Growing community of inventors

Dreieich, Germany

Thomas Haeder